Bicycle Therapeutics plcBCYCNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank52
3Y CAGR-70.4%
5Y CAGR-37.4%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
-70.4%/yr
Quarterly compound
5Y CAGR
-37.4%/yr
Recent deceleration
Percentile
P52
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 1.96% |
| Q2 2025 | 16.06% |
| Q1 2025 | -794.18% |
| Q4 2024 | 75.75% |
| Q3 2024 | 10.76% |
| Q2 2024 | 36.30% |
| Q1 2024 | -49.65% |
| Q4 2023 | -3000.13% |
| Q3 2023 | -104.52% |
| Q2 2023 | 169.72% |
| Q1 2023 | -52.75% |
| Q4 2022 | -304.84% |
| Q3 2022 | 75.82% |
| Q2 2022 | -5.07% |
| Q1 2022 | -168.42% |
| Q4 2021 | -152.94% |
| Q3 2021 | 273.24% |
| Q2 2021 | 12.48% |
| Q1 2021 | 16.20% |
| Q4 2020 | -69.65% |
| Q3 2020 | 20.32% |
| Q2 2020 | -161.22% |
| Q1 2020 | 482.63% |
| Q4 2019 | 51.64% |
| Q3 2019 | -38.37% |
| Q2 2019 | -43.64% |
| Q1 2019 | 39.35% |
| Q4 2018 | -93.65% |
| Q3 2018 | 15.76% |
| Q2 2018 | 24.65% |
| Q1 2018 | -236.02% |
| Q4 2017 | 0.00% |